GenMark Dx Plans Respiratory Viral, CYP450 Panels as Q2 Revenues Rise 162 Percent

Company officials attributed the spike in sales to increased demand for GenMark's FDA-cleared tests for cystic fibrosis, warfarin sensitivity, and thrombophilia risk.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.